At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 378 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Infliximab for Psoriasis. Completed, enrolled 378 participants.
Detailed Summary
The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Study CompletionOct 2004
First PostedApr 2005
TodayJul 2026
First PostedApr 1, 2005
Study CompletionOct 1, 2004
TodayJul 2, 2026
Posted 21.3 years ago
Interventions
Infliximabdrug